ATRC
AtriCure, Inc.41.08
+0.04+0.1%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A dismisses clip rival threat
Q&A downplayed a new competitor's clip entry as market validation, noting past rivals accelerated their open appendage growth to 24% last year while reaffirming 12-14% 2026 guidance with mild back-half pressure baked in. LeAAPS trial passed DSMB review at 50% events with a continue thumbs-up, but no early data release. UK NHS woes sized at a $3M Q4 hit mainly to pain management and MIS ablation. CryoXT rollout remains deliberate, mirroring EnCompass launch for sticky adoption by mid-2026. Hybrid ablation shows stabilization glimmers yet no growth commitment. New rivals? We've grown despite them before. Management stayed confident on innovation edge and trial catalysts.
Key Stats
Market Cap
2.04BP/E (TTM)
-Basic EPS (TTM)
-0.61Dividend Yield
0%Recent Filings
10-K
FY2025 results
AtriCure posted FY2025 revenue of $534.5M, up 14.9% y/y, with Q4 strength in open ablation (+16.3% y/y to $143.8M), pain management (+32.5% y/y to $81.9M), and appendage management (+17.5% y/y to $178.1M), while minimally invasive ablation dropped 31.2% y/y to $31.5M as PFA adoption accelerated. Gross margin edged up to 75.0% on favorable mix, narrowing operating loss to $9.4M from $40.0M; net loss shrank to $11.4M. U.S. drove 81.6% of sales (+13.7% y/y), international +20.2% y/y. Cash hit $167.4M with $61.9M debt. No annual guidance disclosed. Reliance on single-source suppliers risks supply disruptions.
8-K
Q4 revenue up 13.1%
AtriCure posted Q4 2025 revenue of $140.5 million, up 13.1% year-over-year, with full-year sales hitting $534.5 million, a 14.9% rise. Net income swung positive at $1.8 million in Q4 while full-year net loss narrowed to $11.4 million; adjusted EBITDA soared to $61.8 million. Growth stemmed from cryoSPHERE MAX, AtriClip FLEX-Mini, and EnCompass adoption, yet minimally invasive devices dipped. Guides 2026 revenue to $600-610 million.
8-K
AtriCure extends ABL facility
AtriCure locked in a three-year extension of its $125M ABL facility on January 9, 2026, via amendment with JPMCB and lenders, slashing interest rates while axing the minimum utilization covenant. This bolsters working capital firepower amid robust Q4 prelims showing $140.5M revenue, up 13%. Lenders secured all assets; no new risks flagged.
10-Q
Q3 FY2025 results
AtriCure posted Q3 revenue of $134.3M, up 15.8% y/y from $115.9M, flipping to $0.2M operating profit from a $7.4M loss while YTD revenue hit $394.0M (15.5% y/y) with a $11.9M operating loss. Gross margin expanded to 75.5% from 74.9%, fueled by appendage management (+21.5% y/y to $45.5M) and pain management (+27.7% y/y to $20.8M), though minimally invasive ablation dropped 33.2%. Cash swelled to $147.9M on $37.3M operating cash flow; $61.9M debt carries 7.0% effective rate with $61.9M availability under the ABL maturing 2027. August sale-and-leaseback fetched $6.3M cash proceeds for HQ expansion. Revenue thrives despite litigation risks over SentreHEART milestones.
8-K
Q3 revenue up 15.8%
AtriCure posted Q3 revenue of $134.3 million, up 15.8% year over year, with U.S. sales hitting $109.3 million on AtriClip FLEX·Mini and EnCompass growth, while international jumped 22%. Net loss shrank to $0.3 million; adjusted EBITDA soared to $17.8 million. Cash flow? Strong at $30.1 million. Raised 2025 outlook to $532-534 million revenue, $55-57 million adjusted EBITDA.
IPO
Website
Employees
Sector
Industry
AHICF
Asahi Intec Co., Ltd.
18.55+0.00
ANGO
AngioDynamics, Inc.
13.48+0.14
AORT
Artivion, Inc.
45.91+0.54
ATR
AptarGroup, Inc.
122.83+0.50
AVTR
Avantor, Inc.
11.20-0.08
ECIA
Encision, Inc.
0.15+0.00
ICCM
IceCure Medical Ltd.
0.63-0.01
ICUI
ICU Medical, Inc.
147.07-0.96
PLSE
Pulse Biosciences, Inc
14.23+0.10
VTAK
Catheter Precision, Inc.
2.19-0.04